GlassScriptPhysician profile
Melissa L Kramer
NPI 1730671785
$3,664.27
in general payments reported to CMS, 2019-2025
28 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,508 · 2022: $713 · 2023: $765 · 2024: $549 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.46 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $386.03 | 2021-2025 | Airsupra |
| Gilead Sciences, INC. | $365.47 | 2022-2024 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $351.94 | 2022-2024 | Uzedy |
| Novo Nordisk INC | $329.14 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $272.74 | 2021-2022 | |
| Boston Scientific Corporation | $178.99 | 2022-2024 | Watchman Flx |
| Abbott Laboratories | $171.27 | 2023-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $153.72 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $113.83 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $110.53 | 2023 | Rexulti |
| Itamar Medical INC | $103.80 | 2023 | Watchpatone |
| Lilly USA, LLC | $84.26 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.12 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $71.99 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.69 | 2021 | |
| Braeburn INC. | $65.21 | 2023-2025 | Brixadi |
| Kci USA, INC. | $55.19 | 2021-2022 | |
| Alkermes, INC. | $29.17 | 2023-2024 | Vivitrol, Vivitrol |
| Sanofi-Aventis U.S. LLC | $28.32 | 2021 | |
| Indivior INC. | $18.89 | 2024 | Sublocade |
| Merck Sharp & Dohme LLC | $18.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.00 | 2021 | |
| Convatec INC. | $16.30 | 2021 | |
| Amarin Pharma, INC. | $15.83 | 2021 | |
| Organogenesis INC. | $15.56 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.20 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.